Psoriasis lesions showed major changes in endocannabinoid receptor expression compared to healthy skin, pointing to potential drug targets

In psoriatic lesional skin, CB2 (CNR2), TRPA1, TRPV3, PPARD, GPR18, and several serotonin receptors were significantly upregulated, while PPARG, TRPV4, PPARA, and GPR12 were significantly downregulated compared to healthy controls. Non-lesional psoriatic skin showed no significant differences from healthy skin.

Differential gene expression analysis using bulk RNA sequencing data from the Gene Expression Omnibus database. Compared endocannabinoid receptor expression between psoriatic lesional skin, non-lesional skin, and healthy controls.

The finding that endocannabinoid receptor expression changes only in active psoriatic lesions, not in unaffected skin, suggests these changes are tied to active disease rather than a systemic predisposition, making them potential therapeutic targets.

Topical cannabinoid treatments for psoriasis are being explored commercially, but the scientific rationale has been unclear. This study provides molecular evidence for which endocannabinoid targets are actually altered in psoriatic skin, potentially guiding more targeted topical formulations.

Database-derived RNA expression data, not from a controlled experiment. Bulk RNA sequencing cannot identify which specific cell types within the skin show expression changes. Gene expression does not necessarily reflect protein-level receptor function.